logo

Heron Therapeutics Inc. (HRTX)



Trade HRTX now with
  Date
  Headline
5/21/2019 9:15:13 AM Heron Reports Publication Of Results From Phase 3 EPOCH 1 Study Of HTX-011 In Patients Undergoing Bunionectomy
5/9/2019 8:35:39 AM Heron Therapeutics Q1 Net Loss $63.0 Mln Or $0.80/Shr Vs Loss $52.3 Mln Or $0.81/Shr Last Year
4/1/2019 8:38:36 AM Heron Announces EMA Validation Of Marketing Authorisation Application For HTX-011 For Postoperative Pain Management
2/22/2019 8:35:59 AM Heron Therapeutics Q4 Net Loss $49.6 Mln Or $0.63/shr Vs Net Loss $62.5 Mln Or $1.09/shr Prior Year
12/31/2018 8:31:35 AM Heron Therapeutics Says FDA Grants Priority Review Designation For NDA For HTX-011
8/8/2018 8:41:37 AM Heron Therapeutics Q2 Net Loss $38.7 Mln Or $0.54/Shr Vs Loss $42.8 Mln Or $0.80/Shr Last Year
6/25/2018 10:04:24 PM Heron Therapeutics Announces Pricing Of Underwritten Public Offering Of About $200 Mln Of Shares
6/25/2018 4:03:45 PM Heron Therapeutics Announces Public Offering Of Common Stock
6/21/2018 8:08:53 AM Heron : HTX-011 For Postoperative Pain Management Receives Breakthrough Therapy Designation From FDA
6/21/2018 8:05:21 AM Heron Announces Positive Results From Phase 2b Studies Of HTX-011 In Total Knee Arthroplasty And Breast Augmentation
5/10/2018 8:35:40 AM Heron Therapeutics Posts Q1 Net Loss Of $52.3 Mln Or $0.81/share
3/28/2018 4:30:23 PM Heron Therapeutics Announces Proposed Public Offering Of Common Stock